Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa)

S. Segal*, I. Y. Shemesh, R. Blumenthal, B. Yoffe, N. Laufer, Y. Ezra, I. Levy, M. Mazor, U. Martinowitz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

69 Scopus citations

Abstract

Recombinant activated factor VII (rFVIIa, NovoSeven®) was used in three patients with massive obstetric hemorrhage due to placenta previa accreta, rupture of the uterus and pre-eclampsia with HELLP. Administration of the drug markedly decreased the bleeding and enabled control of the hemorrhage. rFVIIa seems to be an adjunctive hemostatic measure for the treatment of severe obstetric hemorrhage.

Original languageEnglish
Pages (from-to)266-267
Number of pages2
JournalArchives of Gynecology and Obstetrics
Volume268
Issue number4
DOIs
StatePublished - Oct 2003

Keywords

  • Factor VIIa
  • Hemorrhage
  • Postpartum hemorrhage

Fingerprint

Dive into the research topics of 'Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa)'. Together they form a unique fingerprint.

Cite this